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Abstract
Suicidality in the child and adolescent population is a major public health concern. There is, however, a lack of developmentally sensi-
tive valid and reliable instruments that can capture data on risk, and clinical and psychosocial mediators of suicidality in young people. 
In this study, we aimed to develop and assess the validity of instruments evaluating the psychosocial risk and protective factors for 
suicidal behaviours in the adolescent population. In Phase 1, based on a systematic literature review of suicidality, focus groups, and 
expert panel advice, the risk factors and protective factors (resilience factors) were identified and the adolescent, parent, and clinician 
versions of the STOP-Suicidality Risk Factors Scale (STOP-SRiFS) and the Resilience Factors Scale (STOP-SReFS) were developed. 
Phase 2 involved instrument validation and comprised of two samples (Sample 1 and 2). Sample 1 consisted of 87 adolescents, their 
parents/carers, and clinicians from the various participating centres, and Sample 2 consisted of three sub-samples: adolescents (n = 259) 
who completed STOP-SRiFS and/or the STOP-SReFS scales, parents (n = 213) who completed one or both of the scales, and the 
clinicians who completed the scales (n = 254). The STOP-SRiFS demonstrated a good construct validity—the Cronbach Alpha for the 
adolescent (α = 0.864), parent (α = 0.842), and clinician (α = 0.722) versions of the scale. Test–retest reliability, inter-rater reliability, 
and content validity were good for all three versions of the STOP-SRiFS. The sub-scales generated using Exploratory Factor Analysis 
(EFA) were the (1) anxiety and depression risk, (2) substance misuse risk, (3) interpersonal risk, (4) chronic risk, and (5) risk due to 
life events. For the STOP-SRiFS, statistically significant correlations were found between the Columbia-Suicide Severity Rating Scale 
(C-SSRS) total score and the adolescent, parent, and clinical versions of the STOP-SRiFS sub-scale scores. The STOP-SRiFS showed 
good psychometric properties. This study demonstrated a good construct validity for the STOP-SReFS—the Cronbach Alpha for the 
three versions were good (adolescent: α = 0.775; parent: α = 0.808; α = clinician: 0.808). EFA for the adolescent version of the STOP-
SReFS, which consists of 9 resilience factors domains, generated two factors (1) interpersonal resilience and (2) cognitive resilience. 
The STOP-SReFS Cognitive Resilience sub-scale for the adolescent was negatively correlated (r = − 0.275) with the C-SSRS total 
score, showing that there was lower suicidality in those with greater Cognitive Resilience. The STOP-SReFS Interpersonal resilience 
sub-scale correlations were all negative, but none of them were significantly different to the C-SSRS total scores for either the ado-
lescent, parent, or clinician versions of the scales. This is not surprising, because the items in this sub-scale capture a much larger 
time-scale, compared to the C-SSRS rating period. The STOP-SReFS showed good psychometric properties. The STOP-SRiFS and 
STOP-SReFS are instruments that can be used in future studies about suicidality in children and adolescents.
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Introduction
Suicide is one of the major causes of death worldwide, 
with figures suggesting that approximately 1 million peo-
ple commit suicide each year [1]. Although completed 
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suicide is rare before the age of 10, suicidal behaviour 
increases sharply during adolescence and is a leading 
cause of death among young people [2]. Several biologi-
cal, social, and psychological risk factors for suicidality 
seem to be shared by children, adolescents, and adults. 
Suicide risk follows a multifactorial trajectory and is 
increased in many psychiatric disorders varying by diag-
nosis, gender, and age [3]. The previous evidence sug-
gests, however, that some risk factors for suicide might 
be different in adolescents compared with adults [4]. In 
adolescents, it is frequent that negative life events precede 
suicidal behaviour, most commonly family conflicts [5–7], 
changes of residence [8], romantic breakup [9], conflict 
with peers, including bullying [10, 11], and/or academic 
failure [12]. These differences in adolescence indicate a 
pressing need for the development of instruments aimed at 
specifically assessing protective and risk factors in young 
people. Considering that many of the adolescents commit-
ting suicide have never received any mental health support 
[13] and that several interventions have shown efficacy in 
preventing suicidal behaviour [14–16], it is essential to 
develop mechanisms that enable identification of subjects 
at risk and promote early intervention. Since suicide is a 
sensitive topic, which can be associated with stigma, web-
based health monitoring platforms could be especially use-
ful tools, as they provide a space for privacy.
To date, there are few valid and reliable, and developmen-
tally sensitive instruments for collecting comprehensive data 
on risk, clinical and psychosocial mediators of suicidality 
in paediatric populations available for use by clinicians [17, 
18]. One of the most widely accepted screening instruments, 
the Columbia-Suicide Severity Rating Scale (C-SSRS), has 
been shown to identify accurately individuals at risk of sui-
cide, both in adult and paediatric populations, and has been 
used as the gold standard for the assessment of suicidal idea-
tion and behaviours in clinical trials [19]; however, its clini-
cal utility has been questioned [20]. One reason for this is 
that the C-SSRS has been deemed not to be sensitive enough 
to be able to capture the full range of suicidal ideation or 
behaviour [20]. The development of the STOP (Suicidality: 
Treatment Occurring in Paediatrics) Risk and Resilience 
Factors Scales has the potential to overcome this limitation 
by addressing the full range of suicidal ideation or behaviour 
whether singly or in combination.
The STOP project (Suicidality: Treatment Occurring 
in Paediatrics http://cordi s.europ a.eu/proje ct/rcn/97369 
_en.html) was predominantly dedicated to the development 
of a comprehensive web-based assessment of suicidality 
and its mediators in children and adolescents. The aim of 
this specific study, which was embedded within the over-
all project, was to develop and assess the validity of the 
multi-informant STOP-Risk Factors Scale (STOP-SRiFS) 
and the multi-informant STOP Resilience Factors Scale 
(STOP-SReFS) as instruments for the collection of com-
prehensive data on psychosocial risk and protective factors 
for suicidal behaviours in the adolescent population.
Methods
Figure 1 shows a general overview of the development and 
validation of the STOP-SRiFS and the STOP-SReFS. Phase 
1 focused on the development of the scales and Phase 2 
focused on their validation. For Phase 2—sample 1 (n = 87), 
the scales were administered to a sample of adolescents, 
their parents/carers, and clinicians (Fig. 1). This sample 
served to explore the psychometric properties of the scales 
(test–retest reliability). Sample 2 consisted of adolescents 
(n = 259) that completed the STOP-SRiFS and/or the STOP-
SReFS scales, parents (n = 213) who completed one or both 
scales, and the young persons’ clinicians (n = 254). The 
samples partially overlapped with one another. Sample 2 
was used for the Exploratory Factor Analyses (EFA) and the 
other psychometric analyses of the scales.
Informed assent/consent was obtained from participants 
and/or their legal representatives, according to the ethical 
and legal standards in the participating countries. The study 
had approval from the Institutional Review Boards of all par-
ticipating sites. Patients were recruited from the secondary/
tertiary clinics from the various participatory Departments 
which were part of the project across the EU. The respiratory 
clinics from King’s College Hospital, London, and Evelina 
London Children’s Hospital contributed to the recruitment 
of the subjects with bronchial asthma and respiratory aller-
gies. Those from the general population were identified 
through advertising on websites, schools, and libraries in 
the UK.
Development of the scales
Systematic literature review A comprehensive and system-
atic literature review was performed at the outset of the 
study to identify the common and frequently reported risk 
and protective factors for suicidality in the paediatric popu-
lation [21]. It also considered the aspects of suicidality that 
were covered by the C-SSRS [20] and other features relat-
ing to the revised nomenclature for the study of suicidal 
behaviours [22].
Selection of items and Scale development For both the 
STOP-SRiFS and STOP-SReFS, three versions (Adolescent, 
Parent and Clinician versions) were designed based on the list 
of domains extracted from the systematic literature review, 
input from focus groups, and expert feedback. The authors fol-
lowed the U.S. Food and Drug Administration (FDA) recom-
mendations for patient outcome measure development [23].
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Consumer feedback: focus groups To explore patient’s 
views on risk and resilience factors of suicidality, identify 
new items, and to verify the understanding of the items, 
six meetings were carried out with children, adolescents, 
and parents (see Fig. 1). Each group session was conducted 
by two clinicians and was recorded with a video camera. 
Notes were taken during each focus group and reviewed by 
the experts. Based on the focus groups, some items were 
simplified, re-worded using age-appropriate vocabulary, or 
dropped; and answer options were reduced and converted to 
a 4-point scoring scale.
Expert feedback: STOP scientific advisory board The 
various experts in the study and the STOP scientific advisory 
board reviewed the draft versions of each scale and sug-
gested minor modifications, which were incorporated into 
the final versions. The final versions of the scales in English 
and Spanish were reviewed by a professional translator. Fol-
lowing this, the English versions were then translated into 
German, Dutch, French, and Italian, and then back-translated 
into English. Clinicians from each participating country in 
the consortium ensured that the meaning of each statement 
remained culturally appropriate and meaningful.
Upload of the scales to HealthTrackerTM Once developed, 
the STOP-SRiFS and STOP-SReFS scales were uploaded 
onto the web-based HealthTracker™ platform, an e-health 
platform that includes a range of different scales for moni-
toring physical or emotional problems [21]. It was decided 
that the risk factors and protective factors would be pre-
sented sequentially as two scales, the STOP-Suicidality 
Risk Factors Scale (STOP-SRiFS) and the STOP-Suicidality 
Fig. 1  General overview of the development and validation of the 
STOP-Suicidality Risk Factors Scale (STOP-SRiFS) and the STOP-
Suicidality Resilience Factors Scale (STOP-SReFS). C-SSRS Colum-
bia-Suicide Severity Rating Scale, EFA exploratory factor analysis, 
HGUGM Hospital General Universitario Gregorio Marañón, Madrid, 
STOP Suicidality: Treatment Occurring in Paediatrics
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Resilience Factors Scale (STOP-SReFS). At the end of this 
process, there are six scales; two for each different role that 
the scale can be assigned to/completed by. The scales are the 
STOP-ReFS for adolescent, parent, and clinicians, and the 
STOP-RiFS for adolescents, parents and clinicians.
Scoring of the scales
The focus groups and the expert panel assisted in deciding 
the response options to the questions and also how to score 
the questions.
Scoring of the STOP‑SRiFS
The majority of the items in the STOP-SRiFS were single 
questions, except for two items (“suicide on internet”, and 
“history of attempt”) that had two sub-questions each. The 
item on “suicide on Internet” dealt with (1) the number of 
times the adolescent had looked up information about sui-
cidal behaviours or acts described in the item; and (2) when 
was the last time that they had searched the internet about 
this. The item on “history of attempt” dealt with (1) the 
number of times that they had attempted suicide in the past, 
and (2) when was the last attempt. For these two items, the 
score was obtained by the sum of the two scores divided by 
two. The score for each STOP-SRiFS questions ranged from 
0 to 4. The undefined answers (“I don’t know”) were coded 
as 888 and then substituted with an empty cell.
Scoring of the STOP‑SReFS
In the STOP-SReFS, each item was composed of two sub-
questions: the first one dealt with the importance the adoles-
cent gave to the item and the second one dealt with how use-
ful the same item was in relation to protecting them against 
suicidality. The score of each item is obtained by the sum 
of the scores of the two sub-questions divided by two. The 
score for the STOP-SReFS items ranged from 0 (not at all) 
to 4 (a great deal). The undefined answers (“I don’t know”) 
were coded as 888 and then substituted with an empty cell. 
Each item score was given by the sum of the two questions 
which composed an item divided by two.
The scales scoring method allows the presence of unde-
fined answers when a subject who filled the scales chose 
“I don’t know” as an answer. This was done to address the 
case in which the subject was unable to decide the answer, 
as forced answers are difficult when dealing with sensitive 
clinical issues such as suicidality. Little’s Missing at Ran-
dom Tests for all the versions of the scales which were run 
before the estimation of the composite scores and for single 
question items. The results of those analyses showed that it 
was not possible to impute a value for the undefined answers, 
and therefore, those were left as empty (not given) answers.
Phase 2: data analyses (validation 
of the instruments)
Subjects completed the questionnaires online using the web-
based HealthTracker™ platform. SPSS version 23 [24] was 
used for the analyses.
Sample 1 Consisted of 87 adolescents, their parents/car-
ers, and clinicians from the various participating centres, 
who were re-administrated the scales within a maximum 
time of 3 weeks. This sample was used to test the time stabil-
ity (test–retest reliability) of all versions of the STOP-SRiFS 
and STOP-SReFS.
Sample 2 Consisted of 259 adolescents, 213 parents of 
adolescents, and 254 clinicians. Completion rates varied, 
because an adolescent might have completed the scale but 
not the parent of the adolescent or the clinician (see Table 2).
Construct validity using Cronbach’s alpha, test–retest 
reliability using correlations between repeat completions 
within 3 weeks, inter-rater reliability through correlations 
between the three versions of the scales, content and con-
current validity, through comparing the scores with that of 
the C-SSRS, and the sub-scales were generated using the 
Exploratory Factor Analysis (EFA) on the Adolescent, Par-
ent, and Clinician versions of the scales. The sample sizes 
for all versions of both scales were above 200 and were 
considered adequate for these analyses [25]. The extraction 
method used was principal axis factoring, and Promax rota-
tion was undertaken.
To assess the concurrent validity, the adolescent, parent, 
and clinician versions of the scales were correlated with the 
C-SSRS using Pearson’s correlations. The previous stud-
ies using the C-SSRS have shown convergent and divergent 
validity with other multi-informant suicidal ideation and 
behaviour scales and high sensitivity and specificity for sui-
cidal behaviour [26].
Results
Sample 1 comprised of 87 adolescents (mean age of 
15.66 ± 1.66; 41.4% males and 58.6% females) (see Table 1 
for the characteristics of Sample 1). Sample 2 was primarily 
composed of adolescents who had been screened as having 
some suicidality on the STOP 4-item Suicidality Screening 
questionnaire [21] and their parents and clinicians. The sam-
ple consisted of 259 adolescents (patient age at first assign-
ment was 15.03 ± 1.599) who completed STOP-SRiFS and/
or the STOP-SReFS scales; 213 parents (patient age at first 
assignment was 14.92 ± 1.797) who filled one or both of the 
scales; and 254 clinicians (patient age at first assignment was 
15.17 ± 1.552) (see Table 2 for demographics of Sample 2). 
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STOP‑SRiFS
1. Construct validity The STOP-SRiFS Adolescent version 
demonstrated a good reliability (Cronbach’s α = 0.864) 
(Cronbach’s threshold was set at α > 0.700 [27]). For the 
Parent version of the scale, two items were excluded, 
because their Corrected Item-Total Correlation (CITC) 
was below the acceptance threshold [“Sexual Iden-
tity” (CITC = 0.056), and “Change of residence” 
(CITC = − 0.158)]. After excluding these two items, the 
STOP-SRiFS Parent version had good Cronbach’s alpha 
value (α = 0.842). Similarly, the STOP-SRiFS Clinician 
version showed a good Cronbach’s alpha (α = 0.722) 
when four items were excluded [chronic physical ill-
ness (CITC = − 0.066), being bullied (CITC = − 0.072), 
use of drugs (CITC = 0.122), and change of residence 
(CITC = 0.045)] (Table 3).
2. Test–retest reliability The results showed that there was 
good temporal stability (test–retest reliability), through 
the intra-class correlation coefficients between the 
STOP-SRiFS sub-scales scores at the first and second 
administration (within 3 weeks ~ 19 Days). All the intra-
class correlations were good (> 0.600) (see Table 4).
3. Inter-rater reliability Table 5 presents the inter-version 
correlations between the different STOP-SRiFS sub-
scales for the adolescent, parent, and clinician versions, 
and shows that they were good (Pearson’s correlation 
coefficient threshold was set at r > 0.200 [27]).
4. Exploratory factor analysis The items that showed poor-
corrected item-total correlation (CITC) for the Parent 
and Clinician versions of the scale were also excluded by 
the EFA and, therefore, from any subsequent psychomet-
ric analysis. The experts in childhood suicidality who 
reviewed these results recommended that the aforemen-
tioned items, given their clinical relevance, should con-
tinue to be administered at the end of the scale as extra 
items, which will not be used in the scoring of the scales. 
As shown in Table 6, EFA for the Adolescent version of 
the STOP-SRiFS (consisting 21 risk factor domains), a 
5-factor model was determined to best fit the data based 
on the screen plot. The Kaiser–Meyer–Olikin (KMO) 
was 0.816 (X2 = 1787.257; Bartlett’s test of sphericity 
Table 1  Description of Sample 1
Developmental range was adolescent for all. Age 15.66 ± 1.66 years
Gender
Male 36
Female 51
Total 87
Ethnicity
Not Set 12
White 67
Asian 1
Chinese 2
Hispanic 5
Total 87
Language
French (France) 20
German (Germany) 6
Italian (Italy) 28
Spanish (Spain) 33
Total 87
Table 2  Description of Sample 2
Adolescent 
sample
Parent 
sample
Clinician 
sample
Treatment group
Aripiprazole 33 30 41
Cognitive behavioural 
therapy
41 41 64
Fluoxetine 68 61 86
General population 55 30 8
Montelukast 8 2 4
Other asthma or allergy 
med
10 3 1
Risperidone 44 46 50
Total 259 213 254
Ethnicity
White 202 171 196
Asian 13 6 3
Black 7 6 8
Mixed 5 6 8
Arabic 1 1 –
Chinese 2 2 1
Hispanic 7 9 9
Gypsy 2 2 2
Ethnicity not set 20 10 27
Total 259 213 254
Gender
Not set – 1 1
Male 94 88 88
Female 165 124 165
Total 259 213 254
Version Completions
Adolescent 259
Parent 213
Clinician 254
Adolescent Parent Clinician
Number 259 213 254
Patient age at first 
assignment
15.03 14.92 15.17
Std. Deviation 1.599 1.797 1.552
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p ≤ 0.001; df = 210). The Parent version of the scale 
without the two items excluded based on the Corrected 
Item-Total Correlation showed again that the best model 
to explain the structure of the scale is again a 5-fac-
tor model. The KMO was 0.720 (X2 = 727.698; Bart-
lett’s test of sphericity p ≤ 0.001, df = 171). The results 
of the EFA for the parent version of the STOP-SRiFS 
showed that the item about the ‘misuse of other drugs’ 
had the highest loading on the factor which assessed the 
sub-domains concerning risk due to life events (0.216). 
The second highest loading for this item (0.179) was 
on the factor which assessed the sub-domains concern-
ing substance misuse risk. Based on the clinical judg-
ment of experts in child and adolescent mental health, it 
was decided that it was clinically relevant for this item 
to be part of the factor about substance misuse risk (see 
Table 6 for more details about the STOP-SRiFS factor 
structure). The Clinician version of the scale (5 factors) 
also presented with a KMO of 0.772 (X2 = 895.861; Bar-
tlett’s test of sphericity p ≤ 0.001, df = 136). Based on 
the pattern of risk factors domain loading, the five fac-
tors were named as: (1) anxiety and depression risk, (2) 
substance misuse risk, (3) interpersonal risk, (4) chronic 
risk, and (5) risk due to life events. These factors cap-
ture the clinical risk clusters in adolescents with suicidal 
ideations or behaviours.
5. Content validity As predicted, the correlations between 
the sub-scales of STOP-SRiFS adolescent version and 
the C-SSRS total score were significant, indicating that 
increased risk was associated with increased C-SSRS 
total score (Table  7). Broadly speaking, the STOP-
SRiFS sub-scale scores in the parent and clinician ver-
sions were similarly correlated with the C-SSRS total 
score. The sub-scale scores that did not reach signifi-
cance were those which would be rated differently by the 
parents and clinicians in comparison to the adolescent 
(Table 7).
STOP‑SReFS
1. Construct validity The Cronbach’s alpha values for all 
the versions of the STOP-SReFS (Adolescent: 0.775; 
Table 3  Cronbach’s alpha values for STOP-SRiFs and STOP-SReFS 
scales
Adolescent 
sample
Parent sample Clinician sample
Cronbach’s alpha
STOP-SRiFS 0.864 0.842 0.722
STOP-SReFS 0.775 0.808 0.808
Table 4  Intraclass correlation coefficients from the STOP-SRiFS and 
STOP-SReFS
Adolescent Parent Clinician
Intraclass correlation coefficient (STOP-SRiFS)
Anxiety and depression risk 0.879 0.933 0.884
Substance misuse risk 0.932 0.980 0.901
Interpersonal risk 0.733 0.606 0.961
Chronic risk 0.736 0.611 0.842
Risk due to life events 0.877 0.909 0.943
Intraclass correlation coefficient (STOP-SReFS)
Cognitive resilience 0.846 0.547 0.866
Interpersonal resilience 0.814 0.764 0.882
Table 5  Inter-version correlation coefficients from the STOP-SReFS 
and the STOP-SRiFS sub-scales
*Correlation is significant at the 0.05 level (two-tailed)
**Correlation is significant at the 0.01 level (two-tailed)
Adolescent Parent Clinician
Inter-version correlations for STOP-SRiFS
Anxiety and depression risk sub-scale
 Adolescent 1 0.537** 0.643**
 Parent 0.537** 1 0.444**
 Clinician 0.643** 0.444** 1
Substance misuse risk sub-scale
 Adolescent 1 0.813** 0.837**
 Parent 0.813** 1 0.781**
 Clinician 0.837** 0.781** 1
Interpersonal risk sub-scale 
 Adolescent 1 0.548** 0.649**
 Parent 0.548** 1 0.490**
 Clinician 0.649** 0.490** 1
Chronic risk sub-scale 
 Adolescent 1 0.314** 0.469**
 Parent 0.314** 1 0.090
 Clinician 0.469** 0.090 1
Risk due to life events sub-scale
 Adolescent 1 0.197* 0.136
 Parent 0.197* 1 0.044
 Clinician 0.136 0.044 1
Inter-version correlations for STOP-SReFS
Cognitive resilience sub-scale
 Adolescent 1 0.105 0.623**
 Parent 0.105 1 − 0.035
 Clinician 0.623** − 0.035 1
Interpersonal resilience sub-scale
 Adolescent 1 − 0.116 0.574**
 Parent − 0.116 1 0.159
 Clinician 0.574** 0.159 1
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Table 6  Exploratory factor analysis for the adolescent, parent, and clinician version of the STOP-SRiFS and STOP-SReFS
STOP-SRiFS Anxiety and 
depression risk
Substance 
misuse risk
Interpersonal risk Chronic risk Risk due to 
life events
Adolescent
Depressive thinking 0.960 − 0.076 − 0.011 0.001 − 0.057
Pessimism 0.928 0.007 0.028 − 0.091 − 0.003
Low self-esteem 0.905 0.009 0.017 − 0.126 0.080
Depressive mood 0.850 0.027 0.020 0.027 − 0.090
Anxiety 0.780 0.036 − 0.075 0.139 − 0.015
Worrying about school performance 0.472 0.036 0.127 0.026 0.091
Misuse of Cannabis 0.000 0.881 − 0.027 − 0.039 − 0.087
Smoking 0.073 0.810 − 0.096 0.066 0.019
Exaggerated use of alcohol − 0.002 0.598 0.076 − 0.170 0.092
Misuse of other drugs − 0.025 0.396 0.019 − 0.028 0.088
Relationship breakup − 0.090 0.345 0.318 0.187 − 0.132
Searching Internet sites about suicide 0.140 − 0.035 0.815 − 0.154 − 0.056
History of suicidal attempt − 0.032 0.024 0.713 0.131 − 0.026
Bullying 0.133 − 0.115 0.247 0.137 0.128
Discomfort with sexual identity − 0.012 0.093 0.231 − 0.093 0.221
Chronic physical condition that produces discomfort 0.006 − 0.100 − 0.123 0.581 − 0.038
Presence of chronic pain 0.079 − 0.097 0.135 0.527 − 0.019
Preoccupation about death of close one − 0.135 0.091 0.049 0.368 0.126
Presence of problems at home 0.281 0.103 0.014 0.301 0.197
Change of residence − 0.065 − 0.011 0.040 − 0.010 0.759
History of completed suicide in the family 0.099 0.061 − 0.151 0.088 0.350
Parent
Pessimism 0.923 − 0.142 0.051 − 0.022 − 0.106
Depressive mood 0.863 0.039 0.002 0.004 − 0.027
Low self-esteem 0.847 0.013 0.058 − 0.034 0.065
Anxiety 0.830 0.052 − 0.016 − 0.017 − 0.015
Depressive thinking 0.677 − 0.051 0.057 0.157 0.227
Worrying about school performance 0.266 0.043 0.219 0.073 0.061
Misuse of cannabis 0.043 0.911 − 0.069 − 0.151 0.031
Smoking 0.071 0.638 0.058 0.122 0.033
Exaggerated use of alcohol − 0.278 0.411 0.221 0.169 − 0.024
Presence of chronic pain 0.101 − 0.003 0.708 0.110 − 0.207
Chronic physical condition that produces discomfort 0.089 0.081 0.588 − 0.223 − 0.110
Searching Internet sites about suicide 0.039 − 0.015 0.007 0.795 − 0.076
History of suicidal attempt 0.211 0.190 0.015 0.430 0.013
Presence of problems at home − 0.012 0.000 0.210 − 0.266 0.735
Relationship breakup − 0.066 − 0.027 0.322 0.175 0.399
Preoccupation about death of close one − 0.067 − 0.054 − 0.175 0.268 0.393
History of completed suicide in the family 0.131 0.038 − 0.235 − 0.088 0.327
Bullying 0.226 0.001 − 0.153 0.183 0.230
Misuse of other drugs 0.038 0.179 − 0.145 0.056 0.216
Clinician
Depressive Thinking 0.896 − 0.071 0.128 − 0.104 − 0.047
Pessimism 0.830 0.079 − 0.074 − 0.017 − 0.072
Low self-esteem 0.759 0.053 − 0.183 − 0.013 0.038
Depressive mood 0.754 0.055 0.057 0.064 − 0.136
Anxiety 0.521 − 0.126 0.009 0.037 0.358
Misuse of cannabis 0.031 0.823 − 0.050 0.012 0.025
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Parent: 0.808; Clinician: 0.808) (Table 3) indicate good 
internal consistency of the scale (Table 3).
2. Test–retest reliability The results showed a good tempo-
ral stability (test–retest reliability). This was assessed in 
Sample 1 through the intra-class correlation coefficients 
Table 6  (continued)
STOP-SRiFS Anxiety and 
depression risk
Substance 
misuse risk
Interpersonal risk Chronic risk Risk due to 
life events
Smoking 0.072 0.780 − 0.120 − 0.029 0.118
Exaggerated use of alcohol − 0.035 0.662 0.146 − 0.062 0.025
History of suicidal attempt − 0.019 − 0.027 0.578 − 0.055 0.052
Discomfort with sexual identity − 0.083 − 0.011 0.392 − 0.078 0.080
Searching Internet sites about suicide 0.209 0.063 0.286 0.202 − 0.032
Presence of problems at home 0.065 − 0.028 − 0.149 0.521 − 0.065
Presence of chronic pain − 0.093 − 0.064 0.012 0.346 0.004
Relationship breakup − 0.056 0.231 0.158 0.309 − 0.016
History of completed suicide in the family 0.021 0.160 0.121 − 0.187 0.357
Preoccupation about death of close one − 0.194 0.119 − 0.001 0.123 0.341
Worrying about school performance 0.175 − 0.068 0.048 0.173 0.289
STOP-SReFS Interpersonal resilience Cognitive resilience
Adolescent
Friendships 0.787 − 0.135
Optimism 0.672 0.070
Hobbies 0.606 − 0.022
Internal control 0.476 0.017
Empathy 0.407 0.271
Religious beliefs 0.234 0.075
Family connectiveness − 0.144 0.920
Social environment 0.373 0.488
External control 0.028 0.217
Parent
Social environment 1.063 − 0.133
Family connectiveness 0.505 0.272
Internal control 0.335 0.119
Empathy − 0.030 0.788
Optimism 0.080 0.634
Friendships 0.254 0.438
Religious beliefs − 0.022 0.334
External control 0.083 0.331
Hobbies 0.275 0.321
Clinician
Social environment − 0.146 0.992
Family connectiveness − 0.087 0.743
Friendships 0.196 0.509
Hobbies 0.191 0.487
Empathy 0.281 0.460
External control 0.049 0.335
Optimism 0.808 0.010
Religious beliefs 0.445 0.021
Internal control 0.423 − 0.030
Extraction method: principal axis factoring, and promax rotation
Numbers in bold indicate the item that the factor belongs to
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between the STOP-SReFS sub-scales scores at the first 
and second administration (within 3 weeks ~ 19 days). 
These results showed that all intra-class correlations 
were above the acceptance threshold (> 0.600), except 
for the parent cognitive resilience scale which was below 
the threshold (0.547) (see Table 4). This is understand-
able, because suicidality risk factors can change even in 
the short period used for the test–retest.
3. Inter-rater reliability Table 5 presents the inter-version 
correlations between the different STOP-SRiFS and 
STOP-SReFS sub-scales for the Adolescent, Parent, and 
Clinician versions, which were all acceptable.
4. Exploratory factor analysis As shown in Table 6, EFA 
for the Adolescent version of the STOP-SReFS identi-
fied that a two-factor model was the best fit (the KMO 
was 0.769 (X2 = 511.748; Bartlett’s test of sphericity 
p ≤ 0.001, df = 36). The EFA of the STOP-SReFS Par-
ent version also showed that the best model to explain 
the structure of the scale was a two-factor model (the 
KMO was 0.819 (X2 = 446.362; Bartlett’s test of sphe-
ricity p ≤ 0.001, df = 36). The EFA of the STOP-SReFS 
Clinician version was similar and had a KMO of 0.813 
(X2 = 572.156; Bartlett’s test of sphericity p ≤ 0.001, 
df = 36). Based on the pattern of resilience factors 
domain loading, the two factors were named: (1) inter-
personal resilience and (2) cognitive resilience. These 
resilience factors are in keeping with known protec-
tive factors. The EFA revealed that the scales were not 
unidimensional and, therefore, precludes the use of a 
total score. In view of this, correlations between the 
STOP-SReFS sub-scales and their correlations with the 
C-SSRS total score were performed.
5. Content validity Correlations between the STOP-SRiFS 
and STOP-SReFS sub-scales, and the C-SSRS total 
score are presented in Table 7. As expected, the C-SSRS 
negatively correlated with the STOP-SReFS (captures 
protective factors) cognitive resilience sub-scale for 
the adolescent (r = − 0.275). However, the clinician 
(r = − 0.143) versions of the scale did not meet the 
threshold of r > 0.200 [26] (Table 7). The STOP-SReFS 
Interpersonal resilience sub-scale correlations were all 
negative, but none of them were significantly different to 
the C-SSRS total scores for either the adolescent, parent, 
or clinician versions of the scales.
Discussion
Despite progress made in suicidality research, the risk and 
resilience factors involved in suicidal behaviour and ideation 
remain poorly understood. The present study describes the 
development and the subsequent psychometric validation of 
two scales: the STOP-Suicidality Risk Factors Scale (STOP-
SRiFS) and the STOP-Suicidality Resilience Factors Scale 
(STOP-SReFS)—two web-based instruments that measure 
elements of suicidality on the web-based HealthTracker™ 
system. The measurement properties of the two instru-
ments were assessed using the consensus-based standards 
for the selection of health status Measurement instruments 
(COSMIN) [28]. The COSMIN checklist was used to struc-
ture the layout of the manuscript when reporting a study 
describing psychometric instruments. Using this approach, 
the psychometric analyses revealed that the STOP-SReFS 
and the STOP-SRiFS were reliable and valid instruments 
for assessing suicidality risk and resilience factors in adoles-
cents. The fact that the STOP-SRiFS and the STOP-SReFS 
are more age-specific scales, which have been designed and 
worded specifically for the adolescent population, and that 
they can be completed online, decreasing completion time 
and ensuring accessibility at all times, increases their poten-
tial applicability in an adolescent population [29]. As sui-
cidal behaviour depends on diverse clinical, psychological, 
sociological, and biological factors, the consensus is that a 
multi-informant evaluation is strongly recommended [21]. 
Furthermore, adolescents who are a particularly high-risk 
group for suicidality differ from the adult population and 
need a deeper, wider, and multi-dimensional approach [30]. 
The study of cross-informant agreement has been shown to 
Table 7  Correlations between 
STOP-SReFS and STOP-SRiFS 
sub-scales, and the C-SSRS 
total score
**Correlation is significant at the 0.01 level (two-tailed)
*Correlation is significant at the 0.05 level (two-tailed)
Adolescent Parent Clinician
Columbia-suicide severity rating scale correlations
STOP-cognitive resilience sub-scale − 0.275** − 0.070 − 0.143*
STOP-interpersonal resilience sub-scale − 0.117 − 0.132 − 0.046
STOP-anxiety and depression risk sub-scale 0.610** 0.426** 0.497**
STOP-substance misuse risk sub-scale 0.221** 0.103 0.097
STOP-interpersonal risk sub-scale 0.491** 0.450** 0.472**
STOP-chronic risk sub-scale 0.287** − 0.029 0.153*
STOP-risk due to life events sub-scale 0.088 0.193** 0.178**
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be useful in obtaining a more detailed understanding of the 
adolescent population [31] as they usually tend to not report 
the same information as their parents, teachers, or clinicians. 
In this study, results in adolescents and parents showed a 
good correlation, contrary to some studies that report low 
agreement between parents and adolescents [32].
The threshold for the minimum loading for EFA was 
set at > 0.200. Thresholds in the region of > 0.200 have 
been cited in the literature [33, 34] and we have previously 
used a similar threshold for factor loading to validate and 
assess the psychometric properties of a parent version of 
a neuropsychiatric scale [35]. In the context of the pre-
sent study, we set a threshold of > 0.200 so that the factor 
loading would best reflect the phenomenon of interest in 
accordance with our sample size, clinical judgement, and 
exploratory nature of the study.
Suicide risk factors have been widely studied, whilst 
the study of protective factors has been usually neglected. 
However, in the past years, there has been an increasing 
interest in incorporating the concept of resilience into the 
suicidality paradigm [36]. The identification of specific 
risk and resilience factors in young people could help to 
develop personalized therapeutic strategies, in which treat-
ment is tailored to the personal needs of each patient. In 
addition, this could lead to the development of targeted 
interventions for some of these risk and/or resilience fac-
tors, for example, intervention programs aimed at improv-
ing the family connectedness. This knowledge may lead to 
actions and changes which can have an impact on the sui-
cide rates as shown in the Youth Aware of Mental Health 
Programme (YAM), a manualized, universal school-based 
intervention which has shown efficacy in reducing the 
number of suicide attempts and severe suicidal ideation 
in adolescents [16]. The SEYLE trial, which has been 
recruiting a large number of European adolescents, has 
also addressed these issues, concluding that screening is 
an efficient method to refer subjects in need of treatment 
[16].
The Internet has become a public and accessible informa-
tion exchange forum for individuals. The use of new tech-
nologies could innovate healthcare, i.e., a web-based version 
of a questionnaire may enhance perceptions of privacy and 
confidentiality, which may improve honesty of responses, 
particularly when less socially desirable, especially to those 
items related to emotions [37].
As far as we are aware of, this is the first attempt to assess 
risk and resilience factors related to suicidality in the adoles-
cent population using web-based measures, and accounting 
for different sources of information. The thorough methodol-
ogy employed, the sample size, the focus groups in which all 
interested parties were involved in co-designing the scales, 
the external scientific supervision by experts in the field, and 
its applicability to multiple pathologies and settings offered 
added value to this study.
Limitations
There are limitations to this study that need to be consid-
ered. To identify subjects at risk, a positive and undefined 
answer to the screening questionnaire of the STOP-Suici-
dality Assessment Scale (STOP-SAS) [21] was necessary 
for patients to be allocated the full STOP-SRiFS and STOP-
SReFS. Since the aim of the study was to develop a universal 
instrument, we did not account for the effect of diagnosis 
and sex on these risk and protective factors. Moreover, not 
being able to substitute the missing values in the database 
with estimations led to a reduced sample size.
Conclusion
The current study suggests that the STOP-SRiFS and the 
STOP-SReFS scales are viable instruments to assess risk 
and resilience factors in young people. They can be used to 
identify subgroups in the adolescent population who may 
need targeted intervention. In this vein, the STOP-SRiFS and 
the STOP-SReFS could be used as effective risk stratifica-
tion tools to provide a multi-informant view on adolescent 
risk for suicidality and maybe of value for the assessment of 
suicidality in clinical trials. This sentiment has been echoed 
by others, who have highlighted the need for improving the 
detection and assessment of suicidality in clinical trials [38]. 
Moreover, the identification of subpopulations with a per-
sonalized level of specific risk and protective factors could 
guide personalized interventions, which ultimately may help 
to reduce suicide rates and improve prognosis in paediatric 
populations.
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